Disc Medicine, Inc. Operating Lease, Liability, Noncurrent
Disc Medicine, Inc. (IRON) had Operating Lease, Liability, Noncurrent of $1.21 million as of 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Other than Long-Term Debt, Noncurrent
us-gaap:OperatingLeaseLiabilityNoncurrent · last filed 2026-07-30
- 2026-06-30: Operating Lease, Liability, Noncurrent $1.21M.
- 2026-03-31: Operating Lease, Liability, Noncurrent $1.28M.
- 2025-12-31: Operating Lease, Liability, Noncurrent $1.25M.
- 2025-09-30: Operating Lease, Liability, Noncurrent $1.37M.
| Period end | Operating Lease, Liability, Noncurrent |
|---|---|
| 2026-06-30 | $1.21M 10-Q · filed 2026-07-30 |
| 2026-03-31 | $1.28M 10-Q · filed 2026-05-05 |
| 2025-12-31 | $1.25M 10-Q · filed 2026-07-30 |
| 2025-09-30 | $1.37M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $1.55M 10-Q · filed 2025-08-07 |
| 2025-03-31 | $1.63M 10-Q · filed 2025-05-07 |
| 2024-12-31 | $1.55M 10-K · filed 2026-02-26 |
| 2024-09-30 | $1.71M 10-Q · filed 2024-11-12 |
| 2024-06-30 | $1.08M 10-Q · filed 2024-08-08 |
| 2024-03-31 | $1.26M 10-Q · filed 2024-05-09 |
| 2023-12-31 | $1.44M 10-K · filed 2025-02-27 |
| 2023-09-30 | $1.61M 10-Q · filed 2023-11-09 |
| 2023-06-30 | $1.77M 10-Q · filed 2023-08-11 |
| 2023-03-31 | $945.00K 10-Q · filed 2023-05-15 |
| 2022-12-31 | $1.03M 10-K · filed 2024-03-21 |
| 2021-12-31 | $1.33M 10-K · filed 2023-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |